Международный неврологический журнал Том 19, №4, 2023
Вернуться к номеру
Основні етіопатогенетичні фактори, особливості клінічного перебігу, діагностики та лікування ішемічного інсульту в осіб молодого віку
Авторы: Дубинецька В.М.
КНП «Центральна міська лікарня» Рівненської міської ради, м. Рівне, Україна
Рубрики: Неврология
Разделы: Справочник специалиста
Версия для печати
Резюме
Дана стаття присвячена актуальній тематиці сьогодення — ішемічним інсультам в осіб молодого віку. На даний час ідентифіковано понад 150 причин ішемічного інсульту, найпоширенішими з яких є антифосфоліпідний синдром, хвороба Фабрі, генетичні мутації, набуті та вроджені тромбофілії, вади серця, низка інфекційних агентів, коморбідні нозології (мігрень), вживання наркотичних середників. Особливу увагу приділено моногенним порушенням, які дебютують з ішемічного інсульту або в яких даний тип інсульту є однією з провідних характеристик. У статті детально висвітлено характерні особливості кожної патології, методи діагностики і шляхи лікування, що є необхідним у роботі лікаря-невропатолога та лікарів інших спеціальностей.
This article deals with the topical issue of today — ischemic strokes in young people. Currently, there are more than 150 identified causes of ischemic stroke, the most common of them are antiphospholipid syndrome, Fabry disease, genetic mutations, acquired and congenital thrombophilia, heart defects, a number of infectious agents, comorbid nosologies (migraine), and the use of narcotic agents. Special attention was paid to the monogenic disorders, which begin from an ischemic stroke or in which this type of stroke is one of the leading characteristics. The article shows in detail the characteristic features of each pathology, methods of diagnosis and ways of treatment, which is necessary in the work of a neuropathologist and doctors of other specialties.
Ключевые слова
огляд; ішемічний інсульт; хвороба Фабрі; моногенні розлади; молодий вік; тромбофілії; дисекція
review; ischemic stroke; Fabry disease; monogenic disorders; young age; thrombophilia; dissection
Для ознакомления с полным содержанием статьи необходимо оформить подписку на журнал.
Список литературы
1. Putaala J. Ischemic Stroke in Young Adults. Continuum (Minneap. Minn.). 2020. Apr. 26(2). 386-414. doi: 10.1212/CON.0000000000000833. PMID: 32224758.
2. Marini C., Russo T., Felzani G. Incidence of stroke in young adults: a review. Stroke Res. Treat. 2010. 2011. 535-672. doi: 10.4061/2011/535672.
3. Sarfo F.S., Ovbiagele B., Gebregziabher M. et al. Stroke among young West Africans: evidence from the SIREN (Stroke Investigative Research and Educational Network) large multisite case control study. Stroke. 2018. 49(5). 1116-1122. doi: 10.1161/STROKEAHA.118.020783.
4. Putaala J., Yesilot N., Waje-Andreassen U. et al. Demographic and geographic vascular risk factor differences in European young adults with ischemic stroke: the 15 cities young stroke study. Stroke. 2012. 43(10). 2624-2630. doi: 10.1161/STROKEAHA.112.662866.
5. von Sarnowski B., Putaala J., Grittner U. et al. Lifestyle risk factors for ischemic stroke and transient ischemic attack in young adults in the Stroke in Young Fabry Patients study. Stroke. 2013. 44(1). 119-125. doi: 10.1161/STROKEAHA. 112.665190.
6. Spector J.T., Kahn S.R., Jones M.R. et al. Migraine headache and ischemic stroke risk: an updated meta-analysis. Am. J. Med. 2010. 123(7). 612-624. doi: 10.1016/j.amjmed.2009.12.021.
7. Adelborg K., Szepligeti S.K., Holland-Bill L. et al. Migraine and risk of cardiovascular diseases: Danish population based matched cohort study. BMJ. 2018. 360. k96. doi: 10.1136/bmj.k96.
8. Malik R., Freilinger T., Winsvold B.S. et al. Shared genetic basis for migraine and ischemic stroke: a genome-wide analysis of common variants. Neurology. 2015. 84(21). 2132-2145. doi: 10.1212/WNL.0000000000001606.
9. Bousser M.G. Estrogens, migraine, and stroke. Stroke. 2004. 35(11 Suppl. 1). 2652-2656. doi: 10.1161/01.STR.0000143223.25843.36.
10. Roach R.E., Helmerhorst F.M., Lijfering W.M. et al. Combined oral contraceptives: the risk of myocardial infarction and ischemic stroke. Cochrane Database Syst. Rev. 2015. 8. CD011054. doi: 10.1002/14651858.CD011054.pub2.
11. Swartz R.H., Cayley M.L., Foley N. et al. The incidence of pregnancy-related stroke: a systematic review andmeta-analysis. Int. J. Stroke. 2017. 12(7). 687-697. doi: 10.1177/1747493017723271.
12. van Alebeek M.E., de Heus R., Tuladhar A.M., de Leeuw F.E. Pregnancy and ischemic stroke: a practical guide to management. Curr. Opin. Neurol. 2018. 31(1). 44-51. doi: 10.1097/WCO.0000000000000522.
13. Alsheikh-Ali A.A., Thaler D.E., Kent D.M. Patent foramen ovale in cryptogenic stroke: incidental or pathogenic? Stroke. 2009. 40(7). 2349-2355. doi: 10.1161/STROKEAHA.109.547828.
14. Goel S.S., Tuzcu E.M., Shishehbor M.H. et al. Morphology of the patent foramen ovale in asymptomatic versus symptomatic (stroke or transient ischemic attack) patients. Am. J. Cardiol. 2009. 103(1). 124-129. doi: 10.1016/j.amjcard. 2008.08.036.
15. Kent D.M., Ruthazer R., Weimar C. et al. An index to identify stroke-related vs incidental patent foramen ovale in cryptogenic stroke. Neurology. 2013. 81(7). 619-625. doi: 10.1212/WNL.0b013e3182a08d59.
16. Hillbom M., Numminen H. Alcohol and stroke: pathophysiologic mechanisms. Neuroepidemiology. 1998. 17(6). 281-287. doi: 10.1159/000026181.
17. Fonseca A.C., Ferro J.M. Drug abuse and stroke. Curr. Neurol. Neurosci. Rep. 2013. 13(2). 325. doi: 10.1007/s11910-012-0325-0.
18. Cheng Y.C., Ryan K.A., Qadwai S.A. et al. Cocaine use and risk of ischemic stroke in young adults. Stroke. 2016. 47(4). 918-922. doi: 10.1161/STROKEAHA.115.011417.
19. Bright C.J., Hawkins M.M., Guha J. et al. Risk of cerebrovascular events in 178 962 five-year survivors of cancer diagnosed at 15 to 39 years of age: the TYACSS (Teenage and Young Adult Cancer Survivor Study). Circulation. 2017. 135(13). 1194-1210. doi: 10.1161/CIRCULATIONAHA. 116.025778.3
20. Grau A.J., Urbanek C., Palm F. Common infections and the risk of stroke. Nat. Rev. Neurol. 2010. 6(12). 681-694. doi: 10.1038/nrneurol.2010.163.
21. Heikinheimo T., Broman J., Haapaniemi E. et al. Preceding and poststroke infections in young adults with first-ever ischemic stroke: effect on short-term and long-term outcomes. Stroke. 2013. 44(12). 3331-3337. doi: 10.1161/STROKEAHA.113.002108.
22. Benjamin L.A., Bryer A., Emsley H.C. et al. HIV infection and stroke: current perspectives and future directions. Lancet Neurol. 2012. 11(10). 878-890. doi: 10.1016/S1474-4422(12)70205-3.
23. Carod-Artal F.J., Gascon J. Chagas disease and stroke. Lancet Neurol. 2010. 9(5). 533-542. doi: 10.1016/S1474-4422(10)70042-9.
24. Sciascia S., Sanna G., Khamashta M.A. et al. The estimated frequency of antiphospholipid antibodies in young adults with cerebrovascular events: a systematic review. Ann. Rheum. Dis 2015. 74(11). 2028-2033. doi: 10.1136/annrheumdis-2014-205663.
25. Alhazzani A.A., Kumar A., Selim M. Association between factor V gene polymorphism and risk of ischemic stroke: an updated meta-analysis. J. Stroke Cerebrovasc. Dis. 2018. 27(5). 1252-1261. doi: 10.1016/j.jstrokecerebrovasdis.2017.12.006.
26. Jiang B., Ryan K.A., Hamedani A. et al. Prothrombin G20210A mutation is associated with young-onset stroke: the genetics of early-onset stroke study and meta-analysis. Stroke. 2014. 45(4). 961-967. doi: 10.1161/STROKEAHA.113.004063.
27. Folsom A.R., Ohira T., Yamagishi K., Cushman M. Low protein C and incidence of ischemic stroke and coronary heart disease: the atherosclerosis risk in communities (ARIC) study. J. Thromb. Haemost. 2009. 7(11). 1774-1778. doi: 10.1111/j.1538-7836.2009.03577.x.
28. Morris J.G., Singh S., Fisher M. Testing for inherited thrombophilias in arterial stroke: can it cause more harm than good? Stroke. 2010. 41(12). 2985-2990. doi: 10.1161/STROKEAHA.110.595199.
29. Cheng Y.C., Stanne T.M., Giese A.K. et al. Genome-wide association analysis of young-onset stroke identifies a locus on chromosome 10q25 near HABP2. Stroke. 2016. 47(2). 307-316. doi: 10.1161/STROKEAHA.115.011328.
30. Debette S., Kamatani Y., Metso T.M. et al. Common variation in PHACTR1 is associated with susceptibility to cervical artery dissection. Nat. Genet. 2015. 47(1). 78-83. doi: 10.1038/ng.3154.
31. Kim S.J., Nogueira R.G., Haussen D.C. Current understanding and gaps in research of carotid webs in ischemic strokes: a review. JAMA Neurol. 2019. 76(3). 355-361. doi: 10.1001/jamaneurol.2018.3366.
32. Ducros A. Reversible cerebral vasoconstriction syndrome. Lancet Neurol. 2012. 11(10). 906-917. doi: 10.1016/S1474-4422(12)70135-7.
33. Kalani R., Liotta E.M., Prabhakaran S. Diagnostic yield of universal urine toxicology screening in an unselected cohort of stroke patients. PLoS One. 2015. 10(12). e0144772. doi: 10.1371/journal. pone.0144772.
34. Pirinen J., Eranti A., Knekt P. et al. ECG markers associated with ischemic stroke at young age — a case-control study. Ann. Med. 2017. 49(7). 562-568. doi: 10.1080/07853890.2017.1348620.
35. Pepi M., Evangelista A., Nihoyannopoulos P. et al. Recommendations for echocardiography use in the diagnosis and management of cardiac sources of embolism: European Association of Echocardiography (EAE) (a registered branch of the ESC). Eur. J. Echocardiogr. 2010. 11(6). 461-476. doi: 10.1093/ejechocard/jeq045.
36. Katsanos A.H., Bhole R., Frogoudaki A. et al. The value of transesophageal echocardiography for embolic strokes of undetermined source. Neurology. 2016. 87(10). 988-995. doi: 10.1212/WNL.0000000000003063.
37. Pagán R.J., Parikh P.P., Mergo P.J. et al. Emerging role of cardiovascular CT and MRI in the evaluation of stroke. Am. J. Roentgenol. 2015. 204(2). 269-280. doi: 10.2214/AJR.14.13051.
38. Lapergue B., Decroix J.P., Evrard S. et al. Diagnostic yield of venous thrombosis and pulmonary embolism by combined CT veno-graphy and pulmonary angiography in patients with cryptogenic stroke and patent foramen ovale. Eur. Neurol. 2015. 74(1–2). 69-72. doi: 10.1159/000437261.
39. Prefasi D., Martinez-Sanchez P., Rodriguez-Sanz A. et al. Atrial fibrillation in young stroke patients: doweunderestimate its prevalence? Eur. J. Neurol. 2013. 20(10). 1367-1374. doi: 10.1111/ene.12187.
40. Zarate Y.A., Hopkin R.J. Fabry’s disease. Lancet. 2008. 372(9647). 1427-1435. doi: 10.1016/ S0140-6736(08)61589-5.
41. Shi Q., Chen J., Pongmoragot J. et al. Prevalence of Fabry disease in stroke patients — a systematic review and meta-analysis. J. Stroke Cerebrovasc. Dis. 2014. 23(5). 985-992. doi: 10.1016/j. jstrokecerebrovasdis.2013.08.010.
42. Benjamin L.A., Corbett E.L., Connor M.D. et al. HIV, antiretroviral treatment, hypertension, and stroke in Malawian adults, a case control study. Neurology. 2016. 86. 324-33. https:// doi. org/ 10. 1212/ WNL. 00000 00000002278.
43. Lammie G.A., Hewlett R.H., Schoeman J.F., Donald P.R. Tuberculous cerebrovasculardisease: a review. J. Infect. 2009. 59. 156-66. https://doi.org/10.1016/j.jinf.2009.07.012.
44. Berger J.R. AIDS and stroke risk. Lancet Neurol. 2004. 3. 206-7 [PubMed: 15039031].
45. Zhou F., Yu T., Du R., Fan G., Liu Y., Liu Z. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020. 395(10229). 1054-1062. doi: 10.1016/S0140-6736(20)30566-3.
46. Beyrouti R., Adams M.E., Benjamin L., Cohen H., Far-mer S.F., Goh Y.Y. Characteristics of ischaemic stroke associated with COVID-19. J. Neurol. Neurosurg. Psychiatry. 2020. 91. 889-891. doi: 10.1136/jnnp-2020-323586.
47. Simone B., De Stefano V., Leoncini E. et al. Risk of venous thromboembolism associated with single and combined effects of Factor V Leiden, Prothrombin 20210A and Methylenetethraydrofolate reductase C677T: a meta-analysis involving over 11,000 cases and 21,000 controls. Eur. J. Epidemiol. 2013. Aug. 28(8). 621-47. doi: 10.1007/s10654-013-9825-8.
48. CADISS Trial Investigators, Markus H.S., Hayter E. et al. Antiplatelet treatment compared with anticoagulation treatment for cervical artery dissection (CADISS): a randomised trial. Lancet Neurol. 2015. 14(4). 361-367. doi: 10.1016/S1474- 4422(15)70018-9.
49. Rombach S.M., Smid B.E., Bouwman M.G. et al. Longterm enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain. Orphanet. J. Rare Dis. 2013. 8. 47. doi: 10.1186/1750-1172-8-47.
50. Stefaniak J.D., Parkes L.M., Parry-Jones A.R. et al. Enzyme replacement therapy and white matter hyperintensity progression in Fabry disease. Neurology. 2018. 91(15). 1413-1422. doi: 10.1212/WNL.0000000000006316.
51. Kernan W.N., Ovbiagele B., Black H.R. et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014. 45(7). 2160-2236. doi: 10.1161/STR.0000000000000024.
52. Meyts I., Aksentijevich I. Deficiency of adenosine deaminase 2 (DADA2): updates on the phenotype, genetics, pathogenesis, and treatment. J. Clin. Immunol. 2018. 38(5). 569-578. doi: 10.1007/s10875-018-0525-8.